601200 Disclosed is a solid oral extended release pharmaceutical dosage form, comprising a melt formed multi particulate extended release matrix formulation, comprising at least one poly(epsilion-caprolactone), and at least one active agent, wherein the extended release matrix formulation further comprises at least one high molecular weight polyethylene oxide having a molecular weight of between about 1,000,000 and about 10,000,000, based on rheological measurements. Also disclosed in the use of the combination of poly(&egr-caprolactone) and high molecular weight polyethylene oxide as matrix forming material in the manufacture of a solid oral extended release pharmaceutical dosage form comprising an active agent selected from opioids for imparting to the solid oral extended release dosage form resistance to milling or alcohol extraction. Further disclosed is the use of the solid oral extended release pharmaceutical dosage form for the manufacture of a medicament for the treatment of pain.
